World's Best Scientists 2026 revealed!
Yves Vanrenterghem

Yves Vanrenterghem

D-Index & Metrics

Medicine

D-Index
96
Citations
31564
World Ranking
9735
National Ranking
110

Overview

Yves Vanrenterghem was affiliated with KU Leuven in Belgium. Their academic career involved contributions to research fields connected to this institution.

There are no recorded recent papers, co-authors, or frequent publication venues attributed to Yves Vanrenterghem in the source data provided.

Information regarding main fields of study, subfields, and specific research topics related to Yves Vanrenterghem is not available.

The source data does not include details about book publications or awards received by Yves Vanrenterghem.

Yves Vanrenterghem is deceased.

Best Publications

  • Reduced exposure to calcineurin inhibitors in renal transplantation.

    Henrik Ekberg;Helio Tedesco-Silva;Alper Demirbas;Štefan Vítko

  • PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION

    J Grinyo;C Groth;R Pichlmayr;Sa Sadek

  • A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

    F. Vincenti;B. Charpentier;Y. Vanrenterghem;L. Rostaing

  • A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

    T van Gelder;L B Hilbrands;Yves Vanrenterghem;W Weimar

  • Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients

    Bert Bammens;Pieter Evenepoel;H Keuleers;Kristin Verbeke

  • The pharmacokinetic‐pharmacodynamic relationship for mycophenolate mofetil in renal transplantation

    Michael D. Hale;Andrew J. Nicholls;Roy E.S. Bullingham;Ronald Hené

  • Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients.

    Sabina De Geest;Liesbeth Borgermans;Hilde Gemoets;Ivo Abraham;Ivo Abraham

  • Prevalence and management of anemia in renal transplant recipients: a European survey

    Yves Vanrenterghem;Claudio Ponticelli;José Maria Morales;Daniel Abramowicz

  • Free p-cresol is associated with cardiovascular disease in hemodialysis patients

    B.K.I. Meijers;B. Bammens;B. De Moor;K. Verbeke

  • Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.

    Barry D. Kahan;Bruce A. Julian;Mark D. Pescovitz;Yves Vanrenterghem

  • Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study

    Pieter Evenepoel;Kathleen Claes;Dirk Kuypers;Bart Maes

  • Calcineurin Inhibitor Minimization in the Symphony Study: Observational Results 3 Years after Transplantation

    Henrik Ekberg;C Bernasconi;H Tedesco-Silva;S Vítko

  • p-Cresol and Cardiovascular Risk in Mild-to-Moderate Kidney Disease

    Björn K.I. Meijers;Kathleen Claes;Bert Bammens;Henriette de Loor

  • p -Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin

    Björn K. I. Meijers;Vicky De Preter;Kristin Verbeke;Yves Vanrenterghem

  • Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients

    G. Opelz;Y. Vanrenterghem;G. Kirste;D. W.r. Gray

  • Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The CAESAR Study

    Henrik Ekberg;J Grinyó;B Nashan;Y Vanrenterghem

  • Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study.

    Bart D. Maes;Raymond Oyen;Kathleen Claes;Pieter Evenepoel

  • Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients.

    Y. Vanrenterghem;L. Roels;T. Lerut;J. Gruwez

  • Three-Year Outcomes From BENEFIT-EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys

    J. O. Medina Pestana;J. M. Grinyo;Y. Vanrenterghem;T. Becker

  • FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.

    Helio Tedesco-Silva;Georges Mourad;Barry D Kahan;Josep Grinyo Boira

Frequent Co-Authors

Dirk Kuypers
Dirk Kuypers KU Leuven
Kathleen Claes
Kathleen Claes Ghent University Hospital
Flavio Vincenti
Flavio Vincenti University of California, San Francisco
Sabina De Geest
Sabina De Geest University of Basel
Josep M. Grinyó
Josep M. Grinyó University of Barcelona
Christian P. Larsen
Christian P. Larsen Emory University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in healthcare but considering options beyond traditional medical school, there are several flexible paths available through online degrees. Many aspiring professionals start with nurse practitioner programs, which prepare you for advanced clinical roles through curricula designed for working adults.

One major concern for students is cost. Understanding how much is online nursing school can help you plan your finances and select a program that fits your budget. From entry-level to advanced degrees, financial accessibility is a top priority.

For nurses seeking teaching or research careers, doctorate in nursing education online programs offer the flexibility to reach the highest levels of academic achievement. For registered nurses wanting career advancement without excessive debt, exploring the cheapest rn to bsn online programs allows you to earn a bachelor’s degree while continuing to work.

With online learning, students can personalize their education, balance work-life commitments, and open new pathways into rewarding healthcare professions.

Best Scientists Citing Yves Vanrenterghem